Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2008 Sep 15;14(18):5643-5.
doi: 10.1158/1078-0432.CCR-08-1557.

Urokinase-type plasminogen activator receptor: a beacon of malignancy?

Affiliations
Comment

Urokinase-type plasminogen activator receptor: a beacon of malignancy?

Ronny Drapkin et al. Clin Cancer Res. .

Abstract

Discriminating between benign and malignant disease is a pivotal diagnostic issue in the care of women with pelvic masses. Identification of serum biomakers that can rellably make the distinction would aid in the proper referral for patient care and may provide leads in the development of early detection strategies.

PubMed Disclaimer

Figures

None
The uPAR is a glycosylated extracellular receptor that is covalently linked to the outer layer of the cell membrane via a glycosyl phosphotidylinositol (GPI) anchor. uPAR consists of three cysteine-rich domains (DI, DII, and DIII) connected by two short linker regions. The N-terminus of the uPAR domain I is the primary site for the binding of uPA.

Comment on

Similar articles

Cited by

References

    1. Jemal A, Siegel R, Ward E, et al. Cancer Statistics 2008. CA Cancer J Clin. 2008;58:71–96. - PubMed
    1. Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351:2519–29. - PubMed
    1. Bast RC, Jr, Klug TL, St John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983;309:883–7. - PubMed
    1. Jacobs IJ, Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics. 2004;3:355–66. - PubMed
    1. Gohagan JK, Prorok PC, Hayes RB, Kramer BS, Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Control Clin Trials. 2000;21:251S–272S. - PubMed

Publication types